The conference highlighted recent advances in the diagnosis and management of obesity, endocrine disorders, diabetes, and growth hormone and thyroid diseases.
Offering choice of CRC screening increases completion rates
May 21, 2024
The rate of colorectal cancer screening improved within six months for those offered fecal immunochemical testing only or a choice of coloscopy or FIT.
Heart, diabetes, cancer drugs on list for Medicare price negotiations, White House says
Aug 29, 2023
Enrollees in the Medicare prescription drug program paid a total of $3.4 billion in out-of-pocket costs in 2022 for the 10 initial drugs chosen for price negotiations.
Decline seen in patients undergoing surgery for colon, rectal cancer in 2020
Apr 11, 2024
Patients undergoing surgery in 2020 versus 2019 had a more advanced clinical and pathological tumor stage.
>10 percent of FIT are unsatisfactory and cannot be processed
Nov 22, 2023
Fewer than half of those with an unsatisfactory FIT completed a subsequent test within 15 months.
Menopausal hormone therapy use beyond 65 years beneficial
Apr 16, 2024
Use of menopausal hormone therapy beyond age 65 years is associated with risk reductions in mortality as well as specific cancers and cardiovascular diseases, according to a study published online April...
17 percent of patients seeing neurologist travel long distance
Sep 13, 2023
Factors associated with long-distance travel include low neurologist density, rural setting and visits for ALS and nervous system cancer.
Overdiagnosis common with continued breast cancer screening in seniors
Aug 09, 2023
An estimated 31% of breast cancers were overdiagnosed among screened women aged 70 to 74 years.
FDA proposes ban on formaldehyde in hair straighteners over health dangers
Oct 18, 2023
Recent research has helped raise awareness about the potential dangers of using chemical hair relaxers.
AACR: Accelerated aging linked to incidence of early-onset cancer
Apr 09, 2024
Accelerated aging was associated with an increased risk for early-onset tumors, driven by lung, gastrointestinal and uterine cancers.